Sentynl Therapeutics, Inc. ("Sentynl") announced that its commercial organization relaunched Abstral® in the United States. Sentynl acquired the rights to market Abstral® from Galena Biopharma in November 2015.
from Business - United States - Latest News http://ift.tt/1UmL3oZ
via IFTTT
No comments:
Post a Comment